S13 Pharmacogenomics Study to Avoid Serious Drug Adverse Reactions S13-1 PGx analyses for preventing adverse reactions caused by anti-cancer drugs S13-2 Pharmacogenomics testing for irinotecan and studies in daily clinical practice S13-3 Statin-induced rhabdomyolysis and genetic marker S13-4 Exploratory study on biomarkers associated with severe cutaneous adverse reactions S13-5 Current status of research in clinical genomics, and guidelines for PGx S13-6 Regulatory perspective to use pharmacogenomics/biomarker in drug safety